Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Nxera Pharma

Tracked across 9 events · 57 articles · First seen Apr 20, 2026 · Last active Sep 03, 2026

Sentiment
32
Attention
4
Events
9
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Nxera Pharma joined the OpenFold consortium to enhance its AI-enabled drug discovery capabilities, particularly for GPCR targets, aligning with its strategy to improve R&D productivity and achieve its 2030 vision. This move is expected to strengthen its competitive position in the biopharmaceutical market.
Jun 10, 2026 · 9 articles
2 70
Business
Impact: Nxera reported strong Q2 results with revenue growth and profitability, driven by milestone payments and progress across its pipeline. The company's strategic partnerships and licensing deals position it for continued growth.
Aug 07, 2026 · 6 articles
4 70
Regulatory
Impact: Nxera is the originator of NBI-1117567 and will receive a US$10 million milestone payment, strengthening its financial position and validating its drug discovery platform.
Aug 26, 2026 · 6 articles
2 20
Business
Impact: Nxera is the recipient of the US$8.6 million milestone payment, which will be recognized as revenue in Q3 2026. This payment reflects progress in its collaboration and supports its drug discovery platform.
Sep 03, 2026 · 6 articles
4 60
Regulatory
Impact: Nxera Pharma holds exclusive rights to AGAMREE in Japan, South Korea, Australia, and New Zealand, and plans to submit a Marketing Authorization Application in South Korea during 2026. This designation will accelerate the review process for AGAMREE.
Jun 02, 2026 · 6 articles
4 0
Tech
Impact: Nxera Pharma holds commercialization rights for AGAMREE in Japan, South Korea, Australia, and New Zealand. Positive clinical data could support future market expansion in its licensed territories.
Jul 01, 2026 · 6 articles
2 0
Business
Impact: Nxera Pharma holds rights for Japan, South Korea, Australia, and New Zealand; not impacted by this expansion.
Jul 13, 2026 · 6 articles
2 0
Business
Apr 23, 2026 · 6 articles
2 0
Business
Apr 30, 2026 · 6 articles
Santhera Pharmaceuticals licensee, investor ↔ Nxera Pharma Nxera Pharma is a licensee of Santhera Pharmaceuticals, having acquired exclusiv
Santhera Pharmaceuticals licensor, investee ↔ Nxera Pharma Santhera Pharmaceuticals is the licensor of vamorolone to Nxera Pharma for speci
ERGEN INTELLIGENCE
Track Nxera Pharma live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.